Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases

In brief

RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of sargramostim after bone marrow transplantation in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00003961

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

1999-04-01

Expected to finish

2007-12-01

Last updated by the study team

2014-04-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.